HKG: 6990

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that SKB575/HBM7575, a long-acting bispecific antibody (bsAb)...

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Fineline Cube Feb 9, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that the National Medical Products Administration (NMPA)...

Company Drug

Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC

Fineline Cube Jan 5, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac‑TMT, SKB264/MK‑2870), its TROP2‑directed...

Company Drug

Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval

Fineline Cube Jan 5, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...

Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Fineline Cube Dec 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving...

Company Drug

Kelun-Biotech’s Sac-TMT Achieves First ADC-IO NSCLC Success

Fineline Cube Nov 24, 2025

Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC,...

Company Drug

Kelun-Biotech’s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1

Fineline Cube Nov 20, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin,...

Company Drug

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer

Fineline Cube Oct 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...

Company Drug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Fineline Cube Oct 13, 2025

China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...

Company Drug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Fineline Cube Sep 23, 2025

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...

Company

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization

Fineline Cube Aug 20, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) released its financial results for the first half...

Company Drug

Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment

Fineline Cube Jul 24, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on July 23, 2025, that its partner...

Company Drug

China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC

Fineline Cube Jun 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that its core product Jiatailai (sacituzumab...

Company Deals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Fineline Cube Jun 5, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...

Company Deals

Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody

Fineline Cube May 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...

Company Drug

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518

Fineline Cube Apr 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...

Company Drug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Fineline Cube Mar 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...

Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company Drug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Fineline Cube Feb 11, 2025

China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...

HKG: 6990

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC

Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Kelun-Biotech’s Sac-TMT Achieves First ADC-IO NSCLC Success

Kelun-Biotech’s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization

Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment

China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

You Missed

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen